Funding provided to develop new therapy for acute liver failure

9 Sep 2015, 4:50 p.m.

Dr Kevin Mills

BRC-supported researcher Dr Kevin Mills has been awarded funding from the NIHR to investigate the regenerative ability of the liver following acute liver failure (ALF). If successful, the team hope that their research will lead to a novel therapy that could buy patients enough time to allow their livers to regenerate naturally, avoiding the need for liver transplantsThis research will be led by Professor Anil Dhawan at Kings College London in collaboration with Dr Mills at UCL Institute of Child Health. Specifically, the team aim to develop a novel technique where human liver cells grown in the lab are encapsulated in a material called alginate and delivered to a patient to help their ailing liver regenerate. Encasing the liver cells in alginate is particularly important as it reduces the need for immunosuppression.

Studies in the lab will focus on the feasibility of this novel therapy under lab conditions.

Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

Scientists build whole functioning thymus from human cells

Researchers from two leading national organisations have rebuilt a human thymus using human stem cells and a bioengineered scaffold thanks to support from the NIHR GOSH Biomedical Research Centre (BRC). Their work, which has been published in Nature Commu

Leukaemia trial shows promise and complexity of genome-edited cell therapies

A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi

GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases

Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe